Incyte’s Pemazyre (pemigatinib) Receives the US FDA’s Approval for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Shots:
- The approval was based on the P-II (FIGHT-203) study that evaluated Pemazyre (13.5mg, qd in 21-day cycles) in 28 patients aged ≥18yrs. with r/r MLNs with FGFR1 rearrangement
- The results showed a CR rate was 78% in patients with chronic phase in marrow with/out EMD; the median time to response was 104 days & median duration of CR was not reached. In patients with blast phase in the marrow with/out EMD & with EMD only, 2 & 1 patients achieved a CR
- The complete cytogenetic response rate was 79% in all patients incl. 3 without evidence of morphologic disease. The company provides a patient support program, IncyteCARES which offers access to eligible patients to use Pemazyre incl. financial assistance, ongoing education & additional resources
Ref: Businesswire | Image: Incyte
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.